MicroRNA Cluster Linked With Kidney Cancer Prognosis

Article

Expression of microRNA (miR)-23b/27b cluster has been linked with increased risk for clear cell RCC disease progression, and may be a predictor of poor survival.

High magnification micrograph of a clear cell renal cell carcinoma. H&E stain. Copyright 2009 Nephron.

Expression of microRNA (miR)-23b/27b cluster has been linked with increased risk for clear cell renal cell carcinoma (RCC) disease progression, and may be a predictor of poor survival, according to the results of a study published recently in the Journal of Urology.

In their prior research, Tomoaki Ishihara, of the department of urology at Kagoshima University, and colleagues found that the miRNAs within the miR-23b/27b cluster were downregulated in cancer tissues. According to the research, this downregulation suggested that this miRNA cluster may be a tumor suppressor in clear cell RCC.

“No effective markers have been identified for predicting RCC recurrence or distant metastases,” the researchers wrote. “Therefore, discovery of novel, specific markers or factors that can predict recurrence or distant metastases after nephrectomy is essential.”

To evaluate this further, the researchers conducted another study to see if there was any association between the miR-23b/27b cluster and outcomes in patients with clear cell RCC. They used 61 samples of clear cell RCC and 61 normal kidney samples from patients who underwent radical nephrectomy or partial nephrectomy between 2004 and 2010. The researchers used quantitative real-time RT-PCR to evaluate the expression levels of miR-23b and miR-27b, and then evaluated any association between miRNA expression and overall survival.

According to data from the patient samples, expression levels of miR-23b and miR-27b were significantly lower in tumor tissues compared with normal kidney samples (P < .0001 for both).

The researchers then divided the samples according to whether there were high or low levels of miR-23b/27b expression. They found that levels of the miRNA were significantly downregulated in patients with T3 stage or higher, and grade 3 tumors.

In addition, results indicated that overall survival was significantly shorter in those patients with low miR-23b/27b expression compared with those patients with high expression levels. However, expression levels alone were not independent predictors of survival.

“Measurement of the expression levels of these miRNAs may be a good prognostic marker for clear cell RCC,” the researchers wrote. “Investigation of molecular networks based on the miR-23b/27b cluster could contribute to elucidation of new molecular mechanisms of clear cell RCC.”

Recent Videos
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Related Content